Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 186.40 |
| Open | 186.35 |
| Bid | 0.00 x 30000 |
| Ask | 0.00 x 30000 |
| Day's Range | 186.35 - 186.35 |
| 52 Week Range | 110.90 - 192.95 |
| Volume | 23 |
| Avg. Volume | 174 |
| Market Cap | 178.714B |
| Beta (5Y Monthly) | 0.24 |
| PE Ratio (TTM) | 33.08 |
| EPS (TTM) | 5.63 |
| Earnings Date | Aug 03, 2021 |
| Forward Dividend & Yield | 2.79 (1.50%) |
| Ex-Dividend Date | May 13, 2021 |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Motley Fool
2 Stocks That Could Be Winners in Alzheimer's Disease Along With Biogen
Biogen (NASDAQ: BIIB) stock skyrocketed after its Alzheimer's disease drug Aduhelm won U.S. Food and Drug Administration (FDA) approval. In this Motley Fool Live video recorded on June 9, Motley Fool contributors Keith Speights and Brian Orelli discuss two stocks that could also be winners along with Biogen.
- Yahoo Finance
Pharmaceutical CEO on Biden’s support for COVID-19 vaccine waiver: ‘It just seems self-defeating’
In May, the Biden administration backed the idea of waiving intellectual property protections for COVID-19 vaccines. In a new interview, pharmaceutical giant Eli Lilly CEO David Ricks weighed in says “this is a counterproductive move.”
- Zacks
Pharma Stock Roundup: AZN COVID-19 Antibody Cocktail Failure, GSK New Cancer Deal
AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.
© 2021 Verizon Media. All rights reserved.
